You are in:Home/Publications/EVALUATION OF HEPATITIS B VIRUS VACCINE IMMUNOGENICITY AMONG HAEMODIALYSIS PATIENTS.

Prof. Hala Mohamad El Feky :: Publications:

Title:
EVALUATION OF HEPATITIS B VIRUS VACCINE IMMUNOGENICITY AMONG HAEMODIALYSIS PATIENTS.
Authors: El Feky HM, *Hashish MA and **Ez El Arab MM.
Year: 2019
Keywords: Not Available
Journal: Not Available
Volume: Not Available
Issue: Not Available
Pages: Not Available
Publisher: Not Available
Local/International: Local
Paper Link: Not Available
Full paper Hala Mohamad El Feky_paper 1.doc
Supplementary materials Not Available
Abstract:

This study was conducted on 50 patients with chronic renal failure on haemodialysis (HD) in end stage renal disease (ESRD) to determinate antibody response pattern after hepatitis B virus vaccination. Also, to identify factors that may affect such response. Each of patient received 3 doses of primary *vaccination; 20 μg were injected i.m. at 0,1,2 and 6 months. Antibody response levels (anti-HBs) were determined after 2 months, 13 patients (26%) were non responder, 13 were poor responder with anti-HBs ≥ 10 IU/L and 24 (48%) were good responder with anti-HBs ≥ 100 IU/L. Significant differences were observed between different response patterns regarding serum ALT, AST, ca levels, associated HCV infection and duration of HD ≤ 24 months. All these were considered as the predictors of good response to HB vaccine. In conclusion, response of HD patients to HB vaccine is inadequate. Therefore, frequent re-evaluation of seroconversion with possible booster doses of HBV vaccination if needed is recommonded.

Google ScholarAcdemia.eduResearch GateLinkedinFacebookTwitterGoogle PlusYoutubeWordpressInstagramMendeleyZoteroEvernoteORCIDScopus